Taurine supplementation: involvement of cholinergic/phospholipase C and protein kinase A pathways in potentiation of insulin secretion and Ca2+ handling in mouse pancreatic islets
Taurine (TAU) supplementation increases insulin secretion in response to high glucose concentrations in rodent islets. This effect is probably due to an increase in Ca2+ handling by the islet cells. Here, we investigated the possible involvement of the cholinergic/phospholipase C (PLC) and protein k...
Saved in:
Published in | British journal of nutrition Vol. 104; no. 8; pp. 1148 - 1155 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Cambridge, UK
Cambridge University Press
28.10.2010
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Taurine (TAU) supplementation increases insulin secretion in response to high glucose concentrations in rodent islets. This effect is probably due to an increase in Ca2+ handling by the islet cells. Here, we investigated the possible involvement of the cholinergic/phospholipase C (PLC) and protein kinase (PK) A pathways in this process. Adult mice were fed with 2 % TAU in drinking water for 30 d. The mice were killed and pancreatic islets isolated by the collagenase method. Islets from TAU-supplemented mice showed higher insulin secretion in the presence of 8·3 mm-glucose, 100 μm-carbachol (Cch) and 1 mm-3-isobutyl-1-methyl-xanthine (IBMX), respectively. The increase in insulin secretion in response to Cch in TAU islets was accompanied by a higher intracellular Ca2+ mobilisation and PLCβ2 protein expression. The Ca2+ uptake was higher in TAU islets in the presence of 8·3 mm-glucose, but similar when the islets were challenged by glucose plus IBMX. TAU islets also showed an increase in the expression of PKAα protein. This protein may play a role in cation accumulation, since the amount of Ca2+ in these islets was significantly reduced by the PKA inhibitors: N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinoline sulfonamide (H89) and PK inhibitor-(6–22)-amide (PKI). In conclusion, TAU supplementation increases insulin secretion in response to glucose, favouring both influx and internal mobilisation of Ca2+, and these effects seem to involve the activation of both PLC–inositol-1,4,5-trisphosphate and cAMP–PKA pathways. |
---|---|
Bibliography: | http://dx.doi.org/10.1017/S0007114510001820 ark:/67375/6GQ-VR179QSW-8 ArticleID:00182 PII:S0007114510001820 istex:6C8E76AEA610AD0863FEECEBBA0F638F3B6E3514 Abbreviations: Cch, carbachol; CTL, control; EGTA, ethylene glycol tetraacetic acid; F340:F380, fluorescence ratio at 340 and 380 nm; H89, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinoline sulfonamide; IBMX, 3-isobutyl-1-methyl-xanthine; IP3, inositol-1,4,5-trisphosphate; KRB, Krebs–Ringer bicarbonate; PK, protein kinase; PKI, protein kinase inhibitor-(6–22)-amide; PMA, phorbol 12-myristate 13-acetate; TAU, taurine ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0007-1145 1475-2662 |
DOI: | 10.1017/S0007114510001820 |